Eculizumab Biosimilar, Anti-human C5 Antibody | Catalog C022P

Eculizumab Biosimilar, Human C5 Monoclonal Antibody. Eculizumab biosimilar CHO stable cell line is available for licensing to manufacture the eculizumab biosimilar protein. The research grade eculizumab biosimilar protein is for research use only (RUO). Recombinant human IgG4 isotype controls and recombinant human IgG2 isotype controls are available.

Product Specifications

Catalog No.	C022P
Product Name	Eculizumab Biosimilar, Human C5 Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Research Grade Anti-Complement Protein C5 Humanized Monoclonal Antibody
Summary	Recombinant Humanized IgG2 Monoclonal Antibody.
Source/Host	Produced in the eculizumab biosimilar CHO stable cell line.
Specificity	Specifically binds to human C5, the terminal complement component 5.

Properties & Storage

Applications	ELISA, functional assays such as bioanalytical PK and ADA assays.
Formulation	0.2 µM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	Shipped with ice pack. Store immediately at recommended temperature.
Storage	12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles.

Background & Description

Eculizumab, a recombinant humanized anti-C5 (terminal complement component 5) monoclonal antibody, selectively targets and inhibits the terminal portion of the complement cascade. Eculizumab is a first-in-class terminal complement inhibitor to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

When activated, C5 at a late stage in the complement cascade is involved in activating host cells, attracting pro-inflammatory immune cells, and destroying cells by triggering pore formation. Eculizumab specifically binds to C5 and inhibits the cleavage of C5 to C5a and C5b, preventing the generation of the terminal complement complex C5b-9.